Litcius/Paper detail

Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO®) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials

Jakub K. Simon, Stephen B. Kennedy, Barbara E. Mahon, Sheri Dubey, Rebecca J. Grant-Klein, Ken Liu, Jonathan Hartzel, Beth-Ann Coller, Carolee Welebob, Mary E. Hanson, Rebecca F. Grais

2022Vaccine26 citationsDOI

Topics & Concepts

Plaque reduction neutralization testMedicineEbola vaccineSierra leoneImmunogenicityVirologyEbola virusTiterPopulationImmunologyVesicular stomatitis virusAntibodyOutbreakVirusEconomicsEnvironmental healthDevelopment economicsViral Infections and Outbreaks ResearchVirology and Viral DiseasesCOVID-19 Digital Contact Tracing
Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO®) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials | Litcius